Sector News

Merck appoints Udit Batra to head combined life science business

April 14, 2015
Life sciences
Merck has appointed Udit Batra, currently Chief Executive Officer and President, Merck Millipore, to lead the combined life science business of Merck Millipore and Sigma-Aldrich once the acquisition of Sigma-Aldrich has been successfully completed.
 
The planned $17 billion transaction remains subject to customary closing conditions and regulatory approvals, which the company expects to have completed in mid-2015. Until then, Merck Millipore and Sigma-Aldrich will continue to operate as separate companies with Udit Batra and Rakesh Sachdev, President and Chief Executive Officer, Sigma-Aldrich, running both organisations independently. Rakesh Sachdev will serve in an advisory capacity, as needed, to ensure a smooth transition.
 
Udit Batra, 44, has served as the Chief Executive Officer and President, Merck’s life science business Merck Millipore since March 2014. He joined Merck in 2011 to head the Group’s Consumer Health business. Prior to that, Udit Batra worked at Novartis Vaccines and Diagnostics, where he was head of global public health and market access. He served in a range of executive management positions at Novartis, including global Head of Corporate Strategy and Country President for the Pharma Business in Australia.
 
Karl-Ludwig Kley, Chairman of the Executive Board of Merck, said, “Udit is a proven leader who has demonstrated his ability to work successfully with his leadership team to guide large organisations, drive performance and deliver to our customers. I also want to express my gratitude to the Sigma-Aldrich employees for building the organisation into a leading global life science tools company and to Rakesh, personally, for providing excellent leadership to the Sigma-Aldrich organisation, both culturally and as demonstrated by the company’s strong performance.”
 

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend